H7N9 Prime-Boost Vaccine Study

Phase 1, open-label trial of H7N9 A/Anhui/13 ca in Influenza A H7N9 Infection (H7N9) (5 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Measurement of the ability of the pLAIV vaccine to induce priming by assessing the response to a subsequent dose of pIIV at Day 118, Measurement of the optimal interval between the priming with pLAIV and the subsequent boost with pIIV at Day 118 and 3 more. Started May 2014; status: completed.